July. 2024. Haibo received a competitive AHA BCVS New Investigator Travel Grant, and attended the AHA BCVS meeting. Many thanks to AHA!
July. 2024. Haibo received a competitive AHA BCVS New Investigator Travel Grant, and attended the AHA BCVS meeting. Many thanks to AHA!
July. 2024. Haibo attended SIAM 2024 and gave an initiated talk on sex differences in atrial fibrillation. This meeting was held in Spokane, WA. His work received an invitation to be covered by the SIAM News!
April. 2024. Haibo Received a Career Development Award from the American Heart Association (AHA)! This award will support Haibo to continue his research of combination pharmacology for atrial fibrillation by building a hybrid platform that integrates computational modeling and engineered human heart techonology. Many thanks to AHA!
Mar. 2024. Our latest preprint, which investigates sex differences in Ca-driven arrhythmias in atrial fibrillation, is available online.
Accumulating evidence demonstrates substantial sex-related differences in atrial fibrillation (AF), which is the most common arrhythmia, with female patients faring worse with the condition. In this study, we aim to gain a mechanistic understanding of the Ca2+-handling disturbances and Ca2+-driven arrhythmogenic events in males vs. females and establish their responses to Ca2+-targeted interventions. By integrating known sex-differential components into our computational spatiotemporal atrial cardiomyocyte model, we found that female vs male atrial cardiomyocytes in AF exhibit greater propensity to developing arrhythmia-promoting spontaneous Ca2+ release events and elevated beat-to-beat variability in action potential-elicited Ca2+ transients. Computational analyses provided novel mechanistic insights into these sex differences. Furthermore, simulations of tentative Ca2+-targeted interventions identified potential treatment strategies that attenuated Ca2+-driven arrhythmogenic events in female atria (e.g., tubule restoration, and inhibition of ryanodine receptor and sarcoplasmic/endoplasmic reticulum Ca2+-ATPase), which reveal additive efficacy when applied in combination. Our study uncovers and validate sex-specific AF mechanisms and establishes that AF treatment may benefit from sex-dependent strategies informed by sex-specific mechanisms.
Feb. 2024. Haibo attended BPS 2024 with colleagues from the Grandi and Morotti Labs.
Highlights from the Grandi lab at BPS 2024: